Looks like you’re on the UK site. Choose another location to see content specific to your location
GlaxoSmithKline’s Nucala shows benefits for treatment of severe asthma
GlaxoSmithKline has presented the findings of a phase IIIb clinical trial that highlights the strong performance of its drug Nucala in the treatment of severe asthma.
A post-hoc analysis of the MUSCA study has indicated that the first-in-class biologic delivered consistent improvements in health-related quality of life and lung function in patients with severe asthma across blood eosinophil levels of 150 cells/mL and above.
The data also showed an association between lung function improvement and increasing eosinophil levels, which represents a useful insight for clinicians making treatment choices for severe asthma patients with an eosinophilic phenotype.
MUSCA was the first study designed to primarily assess the effect of this treatment on disease-specific health-related quality of life.
Dr Frank Albers, global medical affairs lead for Nucala at GlaxoSmithKline, said the study "shows that Nucala has the potential to offer meaningful improvements in important clinical endpoints, as well as patient-reported outcomes, in severe asthma patients with blood eosinophil levels of 150 cells/mL and above".
In Europe, Nucala is licensed as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard